302 related articles for article (PubMed ID: 23327988)
1. Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Chesnais V; Kosmider O; Damm F; Itzykson R; Bernard OA; Solary E; Fontenay M
Oncotarget; 2012 Nov; 3(11):1284-93. PubMed ID: 23327988
[TBL] [Abstract][Full Text] [Related]
2. Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies.
Damm F; Nguyen-Khac F; Fontenay M; Bernard OA
Leukemia; 2012 Sep; 26(9):2027-31. PubMed ID: 22484420
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.
Makishima H; Visconte V; Sakaguchi H; Jankowska AM; Abu Kar S; Jerez A; Przychodzen B; Bupathi M; Guinta K; Afable MG; Sekeres MA; Padgett RA; Tiu RV; Maciejewski JP
Blood; 2012 Apr; 119(14):3203-10. PubMed ID: 22323480
[TBL] [Abstract][Full Text] [Related]
4. The significance of spliceosome mutations in chronic lymphocytic leukemia.
Rozovski U; Keating M; Estrov Z
Leuk Lymphoma; 2013 Jul; 54(7):1364-6. PubMed ID: 23270583
[TBL] [Abstract][Full Text] [Related]
5. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance.
Patnaik MM; Lasho TL; Finke CM; Hanson CA; Hodnefield JM; Knudson RA; Ketterling RP; Pardanani A; Tefferi A
Am J Hematol; 2013 Mar; 88(3):201-6. PubMed ID: 23335386
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biological implications of driver mutations in myelodysplastic syndromes.
Papaemmanuil E; Gerstung M; Malcovati L; Tauro S; Gundem G; Van Loo P; Yoon CJ; Ellis P; Wedge DC; Pellagatti A; Shlien A; Groves MJ; Forbes SA; Raine K; Hinton J; Mudie LJ; McLaren S; Hardy C; Latimer C; Della Porta MG; O'Meara S; Ambaglio I; Galli A; Butler AP; Walldin G; Teague JW; Quek L; Sternberg A; Gambacorti-Passerini C; Cross NC; Green AR; Boultwood J; Vyas P; Hellstrom-Lindberg E; Bowen D; Cazzola M; Stratton MR; Campbell PJ;
Blood; 2013 Nov; 122(22):3616-27; quiz 3699. PubMed ID: 24030381
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
Liu YC; Illar GM; Bailey NG
J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
[TBL] [Abstract][Full Text] [Related]
8. SF3B1 mutant myelodysplastic syndrome: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
[TBL] [Abstract][Full Text] [Related]
9. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
[TBL] [Abstract][Full Text] [Related]
10. Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes.
Yip BH; Dolatshad H; Roy S; Pellagatti A; Boultwood J
Curr Pharm Des; 2016; 22(16):2333-44. PubMed ID: 26916023
[TBL] [Abstract][Full Text] [Related]
11. Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures.
Jenkins JL; Kielkopf CL
Trends Genet; 2017 May; 33(5):336-348. PubMed ID: 28372848
[TBL] [Abstract][Full Text] [Related]
12. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
Brierley CK; Steensma DP
Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
[TBL] [Abstract][Full Text] [Related]
13. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
[TBL] [Abstract][Full Text] [Related]
14. Somatic
Foy A; McMullin MF
J Clin Pathol; 2019 Nov; 72(11):778-782. PubMed ID: 31473630
[TBL] [Abstract][Full Text] [Related]
15. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome.
Mian SA; Smith AE; Kulasekararaj AG; Kizilors A; Mohamedali AM; Lea NC; Mitsopoulos K; Ford K; Nasser E; Seidl T; Mufti GJ
Haematologica; 2013 Jul; 98(7):1058-66. PubMed ID: 23300180
[TBL] [Abstract][Full Text] [Related]
16. Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies.
Taylor J; Lee SC
Genes Chromosomes Cancer; 2019 Dec; 58(12):889-902. PubMed ID: 31334570
[TBL] [Abstract][Full Text] [Related]
17. Spliceosomal factor mutations and mis-splicing in MDS.
Hershberger CE; Daniels NJ; Padgett RA
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101199. PubMed ID: 33038983
[TBL] [Abstract][Full Text] [Related]
18. Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors.
Scott LM; Rebel VI
J Natl Cancer Inst; 2013 Oct; 105(20):1540-9. PubMed ID: 24052622
[TBL] [Abstract][Full Text] [Related]
19. Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders.
Visconte V; Makishima H; Maciejewski JP; Tiu RV
Leukemia; 2012 Dec; 26(12):2447-54. PubMed ID: 22678168
[TBL] [Abstract][Full Text] [Related]
20. Spliceosome mutations in hematopoietic malignancies.
Hahn CN; Scott HS
Nat Genet; 2011 Dec; 44(1):9-10. PubMed ID: 22200771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]